Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Allellic frequencies of CTLA-4 49A/G polymorphism among patient controls

From: CTLA-4+49A/G and CT60 gene polymorphisms in primary Sjögren syndrome

CTLA-4+49A/G Allele frequencies p Odds ratio (95% CI)
  pSS SSA+ and SSB+ SSA+ only Ac+ Ac0 Controls (n = 241)   
Cohort 1 n = 142 n = 47 n = 43 n = 90 n = 52    pSS vs controls
   A (Thr) 208 (73) 68 (72) 61 (71) 129 (72) 79 (76) 318 (66) 0.036 1.41 (1.02–1.95)
   G (Ala) 76 (27) 26 (28) 25 (29) 51 (28) 25 (24) 164 (34) 0.036 0.70 (0.51–0.98)
Cohort 2 n = 139 n = 52 n = 49 n = 101 n = 38 Controls (n = 241)   
   A (Thr) 173 (62) 59 (57) 66 (67) 125 (62) 48 (63) 318 (66) NS 0.85 (0.62–1.15)
   G (Ala) 105 (38) 45 (43) 32 (33) 77 (38) 28 (37) 164 (34) NS 1.17 (0.86–1.60)
Total n = 281 n = 99 n = 92 n = 191 n = 90 Controls (n = 241)   
   A (Thr) 381 (68) 127 (64) 127 (69) 254 (66) 127 (71) 318 (66) NS 1.08 (0.84–1.40)
   G (Ala) 181 (32) 71 (36) 57 (31) 128 (34) 53 (29) 164 (34) NS 0.92 (0.71–1.19)
  1. Numbers in parentheses are percentages. pSS, primary Sjögren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.